SCHEMBL770373

SCHEMBL770373

O=C(CC(=O)N1CCC2CCCC=C2C1)N1CCN(C(c2ccccc2)c2ccccc2)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNA2D1 P54289 10/20 0.54
CACNB1 Q02641 10/20 0.54
CACNA1B Q00975 9/20 0.54
CACNA1C Q13936 7/20 0.54
CACNA1H O95180 1/20 0.54
NPSR1 Q6W5P4 3/20 0.48
CNR1 P21554 2/20 0.48
CNR2 P34972 2/20 0.48
HTT P42858 1/20 0.48
CACNA1G O43497 1/20 0.48
ALDH1A1 P00352 2/20 0.48
USP2 O75604 1/20 0.48
MAPK1 P28482 1/20 0.48
CACNA1A O00555 2/20 0.47
NPC1 O15118 1/20 0.47
KMT2A Q03164 2/20 0.46
KDM4E B2RXH2 1/20 0.46
MAPT P10636 1/20 0.46
HPGD P15428 1/20 0.46
MEN1 O00255 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL770497 0.95 CACNA2D1 (0.53) CACNA2D1CACNB1CACNA1BCACNA1CCACNA1H
SCHEMBL771261 0.93 CACNA2D1 (0.51) CACNA2D1CACNB1CACNA1BCACNA1CCACNA1H
SCHEMBL770395 0.89 CNR1 (0.50) CACNA2D1CACNB1CACNA1BCACNA1CCACNA1H
SCHEMBL771469 0.81 MEN1 (0.49) ALDH1A1KMT2AKDM4EMEN1
SCHEMBL770397 0.81 ALDH1A1 (0.36) HTTALDH1A1NPC1KMT2AMAPT
SCHEMBL770523 0.80 CACNA2D1 (0.54) CACNA2D1CACNB1CACNA1BCACNA1CCACNA1H
SCHEMBL770894 0.80 KDM1A (0.39) CACNA2D1CACNB1CACNA1BCACNA1CHTT
SCHEMBL770666 0.80 RBP4 (0.44) CNR1ALDH1A1NPC1MAPT
SCHEMBL770187 0.80 TSHR (0.49) HTTALDH1A1KMT2AKDM4EMAPT
SCHEMBL770075 0.79 ALDH1A1 (0.42) ALDH1A1NPC1KMT2AHPGDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822452-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2014-09-02 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-8524894-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2013-09-03 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 CACNA2D1 3305/4885CACNB1 4111/4885CACNA1B 3651/4885
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 CACNA2D1 3302/4885CACNB1 4104/4885CACNA1B 3638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.